×
0 0.04 0.18 0.1 0.1 0.02 0.0439000000000001 0.02
Stockreport

The Female Health Company / Veru Healthcare Announces Successful Stage 1 of the Clinical Trial to Evaluate Bioequivalence Between Tamsulosin DRS and FLOMAX®

FEMALE HEALTH (FHCO)  More Company Research Source: GlobeNewswire
US:NASDAQ Investor Relations: verupharma.com/investors
PDF --Stage 1 of Clinical Trial Completed; A Tamsulosin DRS Formulation is Selected That Demonstrates Profile Similar to FLOMAX® and May Provide Other Potential Advantages, Including Ease-of-Use and Safety Benefits; New Tamsulosin DRS Formulation Advances to Stage 2; Planned NDA Filing Under the 505(b)(2) Regulatory Pathway On Track; Approval Expected in Second Half of 2018-- MIAMI, April 12, 2017 (GLOBE NEWSWIRE) -- The Female Health Company / Veru Healthcare (NASDAQ:FHCO) today announced the successful Stage 1 of a bioequivalence (BE) clinical trial which was designed to select the optimal formulation of its proprietary Tamsulosin Delayed Release Sachet (DRS) product.  Tamsulosin DRS is a new, slow release oral powder formulation that addresses the large patient population of men with benign prostatic hyperplasia (BPH) who have difficulty swallowing ta [Read more]

IMPACT SNAPSHOT EVENT TIME: FHCO
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
FHCO alerts
from News Quantified
Opt-in for
FHCO alerts

from News Quantified
Opt-in for
FHCO alerts

from News Quantified